Accordingly, transwell and migration assays showed that miR-181a inhibitor reversed the inhibitory role of si-ANRIL on the invasiveness and migration of pancreatic cancer cells (Figure 2C and 2D). This evidence concerns the gene CDKN2B-AS1 and familial pancreatic carcinoma.